Gliclazide: Protection of the Microvasculature
Gliclazide stands out among other antidiabetic agents due to its unique metabolism. In the body, it is transformed into eight metabolites, with one playing a key role by exerting specific hemorheological effects on the microcirculation system.
Its impact on the vascular bed is mediated through four main mechanisms:
- Antiplatelet effect: significantly reduces platelet aggregation.
- Anticoagulant action: exerts heparin-like effects on plasma coagulation factors.
- Fibrinolytic activity: promotes the dissolution of existing blood clots (fibrinolysis).
- Antioxidant defense: suppresses oxidative stress that damages the vascular wall.
Due to these properties, the drug provides pronounced organ protection. It improves tissue vascularization and trophic state (particularly evident in the conjunctiva) and eliminates vascular stasis. In clinical practice, this reduces the severity of diabetic angiopathies, nephropathies, and retinopathies. Therefore, gliclazide is a preferred agent for patients with type 2 diabetes who have already developed vascular complications.
Glimepiride: Mechanism of Action and Selectivity
Glimepiride is a third-generation sulfonylurea derivative. Its primary target is the ATP-sensitive potassium channels ($K_{ATP}$ channels) located on the membranes of pancreatic $\beta$-cells. The drug specifically interacts with a 65 kDa protein subunit of the channel.
A crucial pharmacodynamic feature is its unique binding kinetics: the molecule associates very rapidly with the receptor and dissociates equally quickly. This provides two significant clinical advantages:
- A rapid therapeutic onset.
- Effective glycemic control with a reduced risk of severe hypoglycemia.
Furthermore, the drug exhibits high tissue selectivity for pancreatic $K_{ATP}$ channels. Its affinity for homologous channels in the myocardium and blood vessels is significantly lower than that of older sulfonylureas, ensuring high cardiovascular safety and minimizing adverse cardiovascular events.
Pharmacokinetics and Extrapancreatic Effects of Glimepiride
The pharmacokinetic profile of glimepiride is characterized by high stability. After oral administration, absolute bioavailability reaches 100%, and plasma protein binding is approximately 99%. The maximum plasma concentration ($C_{max}$) is reached within 2.5 hours, and the volume of distribution ($V_d$) is about 8.8 liters.
Metabolism occurs in the liver, yielding two main active metabolites: a hydroxylated and a carboxylated derivative. Excretion takes place via both the kidneys and the gastrointestinal tract. The elimination half-life ($t_{1/2}$) ranges from 5 to 8 hours.
Despite a relatively short half-life, the total duration of the hypoglycemic effect exceeds that of older sulfonylureas, enabling a convenient once-daily dosing regimen.
In addition to its pancreatic effects, glimepiride exerts important extrapancreatic actions, notably an antiplatelet effect. This is achieved by inhibiting the enzyme cyclooxygenase (COX), which subsequently blocks thromboxane synthesis within platelets.